Huntington's Disease clinical trials at UCSD
4 in progress, 2 open to eligible people
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.
open to eligible people ages 25-50
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease.
La Jolla, California and other locations
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
open to eligible people ages 18 years and up
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 20,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.
San Diego, California and other locations
PTC518 in Participants With Huntington's Disease (HD)
Sorry, not currently recruiting here
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
La Jolla, California and other locations
Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD
Sorry, in progress, not accepting new patients
SHIELD HD is an international, multisite, prospective, longitudinal cohort natural history study to assess the natural history of HD and its biomarkers that are associated with modulation of the number of cytosine-adenine-guanine (CAG) repeats in the mutant Huntingtin (HTT) gene. Approximately 60 patients will be enrolled into the study and followed for up to 24 months at clinical sites in North America and Europe. The results of this study will inform assessments for a future interventional treatment trial.
San Diego, California and other locations
Our lead scientists for Huntington's Disease research studies include Jody Corey-Bloom.
Last updated: